# **Baseline Characteristics of Patients Enrolled in the Teri-PRO Phase 4 Study** in the United States vs Canada, Europe, and Latin America

Patricia K Coyle,<sup>1</sup> Christopher LaGanke,<sup>2</sup> Bhupendra Khatri,<sup>3</sup> Ralf Gold,<sup>4</sup> Steve Cavalier,<sup>5</sup> Sandrine Brette,<sup>6</sup> Francesca Baldinetti,<sup>5</sup> Keith R Edwards<sup>7</sup>

<sup>1</sup>Stony Brook University, Stony Brook, NY, USA; <sup>2</sup>North Central Neurology Associates, Cullman, AL, USA; <sup>3</sup>The Regional MS Center, Center for Neurological Disorders at Wheaton Franciscan Healthcare, Milwaukee, WI, USA; <sup>4</sup>St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany; <sup>5</sup>Genzyme, a Sanofi company, Cambridge, MA, USA; <sup>6</sup>Lincoln, Boulogne-Billancourt, France; <sup>7</sup>Multiple Sclerosis Center of Northeastern New York, Latham, NY, USA

## **INTRODUCTION**

- Teriflunomide is a once-daily oral immunomodulator approved for relapsingremitting MS
- Teriflunomide has demonstrated consistent efficacy in patients with relapsing forms of MS<sup>1-3</sup> and in patients who experienced a first clinical episode suggestive of MS<sup>4</sup> in placebo-controlled clinical trials. It also has a wellcharacterized and manageable safety and tolerability profile<sup>1-4</sup>
- Patient-reported outcomes (PROs) are important measures that complement clinical evaluations and are applied to evaluate experience and satisfaction of patients with their treatment; consequently, PRO measures also provide insight into patients' health-related quality of life
- The ongoing phase 4 Teri-PRO (Teriflunomide Patient-Reported Outcomes; NCT01895335) study is evaluating the efficacy and tolerability of and satisfaction with teriflunomide in clinical practice
- Patients entering Teri-PRO were recruited across sites in North America, Europe, and Latin America


## **OBJECTIVES**

• To describe demographics and baseline disease characteristics of patients enrolled in Teri-PRO in the United States and the rest of the world (ROW), including Canada, Europe, and Latin America

## **METHODS**

## **Study Design and Patients**

• Teri-PRO is a global, prospective, single-arm, multicenter, open-label study (Figure 1)



Timing of efficacy and safety assessments. All patient screening and monitoring to be performed as per local labeling. Patients continuing treatment after Teri-PRO will have the opportunity to switch to commercial teriflunomide.

- Patients with relapsing forms of MS (N=1001) aged ≥18 years were recruited across sites in the United States, Canada, Europe (Austria, Belgium, Finland, France, Germany, Greece, Italy, Norway, Spain, Sweden, and the United Kingdom), and Latin America (Chile)<sup>5</sup>
- Reflecting the routine clinical practice setting, there were no disease activity eligibility criteria; full exclusion criteria have been presented previously
- Patients were prescribed teriflunomide 14 mg or 7 mg once daily for 48 weeks according to local labeling; in the United States, where the 7-mg dose is available, choice of dose was determined by the treating neurologist
- Patients could enter Teri-PRO, regardless of previous use of disease-modifying therapy (DMT) and were classified into the following groups:
- Patients with no DMT intake in the past 2 years
- Patients with last DMT intake within 2 years of study entry
- Patients with last DMT intake 6–24 months before study entry • Patients with last DMT intake within 6 months of study entry (considered "switchers")

## **Study Outcomes**

- The primary endpoint of Teri-PRO is global satisfaction with teriflunomide treatment at Week 48 (or end of treatment [EOT] if treatment was discontinued before Week 48), as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM, version 1.4)<sup>6</sup>
- Secondary endpoints include:
- Change in TSQM from baseline to Week 4 and from baseline to Week 48 (or EOT) in patients switching from another DMT
- Change in TSQM from Week 4 to Week 48 (or EOT) in patients with no DMT intake in the past 2 years
- Changes from baseline in other PROs<sup>5</sup>
- Clinical outcomes, including treated relapses, time to first treated relapse, and Expanded Disability Status Scale (EDSS) score
- Occurrence of adverse events

#### **Timing of Assessments**

- All efficacy and safety measures will be assessed at baseline and at Week 48/ EOT. The following measures will also be assessed at other times:
- TSQM: Week 4 and Week 48/EOT in all patients, and baseline, Week 4, and Week 48/EOT in patients switching from another DMT
- Treated relapses: Baseline and Weeks 4, 24, and 48/EOT
- Adverse events: Reported at each visit

### **Analysis Population**

• All patients who receive ≥1 dose of teriflunomide are included in the efficacy and safety analyses

## RESULTS

- Teri-PRO enrollment is complete; 1001 patients were included in the study and 1000 patients were treated
- In the United States:
- Patients were enrolled between June 21, 2013, and June 24, 2014, inclusive
- Of 611 US patients screened, 545 were included in Teri-PRO. Teriflunomide 14 mg and 7 mg were prescribed to 473 patients (86.8%) and 72 patients (13.2%), respectively
- In the ROW (Canada, Europe, and Latin America):
- Patients were enrolled between March 3, 2014, and November 27, 2014, inclusive
- Of 491 ROW patients screened, 456 were included in Teri-PRO and 455 were prescribed teriflunomide 14 mg
- Demographic and baseline disease characteristics are detailed in Table 1
- Patients in the US group were generally older than those in the ROW (mean age 50.6 vs 42.9 years, respectively) and had a longer duration of disease (14.7 vs 11.3 years, respectively)
- The ROW group contained a higher proportion of Caucasian/white patients (98.9%) compared with the US group (89.7%)
- The median time since most recent relapse was longer in the ROW group (14.7 months) compared with the US group (10.1 months)
- The frequency distribution of EDSS scores at baseline is shown in Figure 2 - Baseline EDSS scores were generally lower for ROW patients compared with US patients
- Regardless of the location of participating patients, the most frequent reason given by physicians for choosing treatment with teriflunomide was the convenience associated with oral therapy; this was followed by side effects/risk of side effects with previous DMT (Figure 3)
- For both the US and the ROW, most patients (n=385, 70.6% and n=327, 71.9%, respectively) were treated with  $\geq$ 1 DMT within the last 2 years before study entry (Table 1)

Table 1. Patient Demographic and Baseline Disease Characteristics			
Characteristic	United States (n=545)	ROW (n=455)	All (N=1000)
Age, mean (SD), y	50.6 (10.5)	42.9 (10.1)	47.1 (11.0)
Female, n (%)	414 (76.0)	344 (75.6)	758 (75.8)
Race, n (%) Asian Black Caucasian/white Other	0 49 (9.0) 489 (89.7) 7 (1.3)	3 (0.7) 1 (0.2) 450 (98.9) 1 (0.2)	3 (0.3) 50 (5.0) 939 (93.9) 8 (0.8)
Time since first symptom of MS, mean (SD), y	14.7 (9.8)	11.3 (8.9)	13.2 (9.5)
Time since most recent relapse onset, mo Median (min:max) Mean (SD)	10.1 (0.0:372.2) <sup>a</sup> 32.1 (51.8) <sup>a</sup>	14.7 (0.1:358.0) <sup>b</sup> 29.7 (39.9) <sup>b</sup>	12.4 (0:372.2) <sup>c</sup> 31.0 (46.6) <sup>c</sup>
Number of relapses within past 2 years, n (%) 0 1 2 3 ≥4	196 (36.1) <sup>d</sup> 182 (33.5) <sup>d</sup> 77 (14.2) <sup>d</sup> 36 (6.6) <sup>d</sup> 52 (9.6) <sup>d</sup>	163 (35.8) 154 (33.8) 85 (18.7) 37 (8.1) 16 (3.5)	359 (36.0) <sup>e</sup> 336 (33.7) <sup>e</sup> 162 (16.2) <sup>e</sup> 73 (7.3) <sup>e</sup> 68 (6.8) <sup>e</sup>
Baseline EDSS score, median (min:max)	3.5 (0.0:8.0) <sup>d</sup>	2.0 (0.0:8.0) <sup>f</sup>	2.5 (0.0:8.0) <sup>g</sup>
Previous DMT within past 2 years, n (%) No Yes Not within past 6 months Switchers <sup>h</sup>	160 (29.4) 385 (70.6) 69 (12.7) 316 (58.0)	128 (28.1) 327 (71.9) 50 (11.0) 277 (60.9)	288 (28.8) 712 (71.2) 119 (11.9) 593 (59.3)

n=518; bn=451; cn=969; dn=543; cn=998; fn=452; gn=995; bdefined as patients with last prior DMT administration date within 6 months before first teriflunomide intake. Efficacy populatic

DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; ROW, rest of the world; SD, standard deviation






Figure 3. Reasons for Treating Patients With Teriflunomide According to cians for US and ROW Patients



Efficacy population. More than 1 reason for treating could be documented. Other reasons cited by physicians included irst DMT treatment for patient, financial considerations, and needle phobia/injection fatigue DMT, disease-modifying therapy; ROW, rest of the world.

#### • For patients who switched to teriflunomide within 6 months of discontinuing another DMT in both the US and ROW (n=316, 58.0% and n=277, 60.9%, respectively), the most common prior therapies before study entry included interferon beta-1a, glatiramer acetate, and dimethyl fumarate (Figure 4)

**QL02** 



## **CONCLUSIONS**

- Comparison of baseline characteristics of patients enrolled in Teri-PRO indicates some differences between US patients and those from other regions, which may reflect differences in prescribing practices and overall disease management
- Teri-PRO will provide valuable information on the use of teriflunomide in clinical practice, including patient treatment satisfaction, safety, and efficacy. This real-world experience will complement existing data from phase 2 and 3 clinical trials

## REFERENCES

1. O'Connor et al. Neurology. 2006;66:894. 2. O'Connor et al. N Engl J Med. 2011;365:1293. 3. Confavreux et al. Lancet Neurol. 2014;13:247. 4. Miller et al. Lancet Neurol. 2014;13:977. 5. Coyle et al. Poster P078, ACTRIMS ECTRIMS 2014. 6. Atkinson et al. Health Qual Life Outcomes. 2004;2:12.

#### Acknowledgments

This poster was reviewed by Larisa Miller, PharmD, of Genzyme, a Sanofi company. Editorial support for this poster was provided by Margarita Lens, of Fishawack Communications, and was funded by Genzyme.

#### Disclosures

PKC: Consulting fees (Abbvie, Acorda, Accordant, Baver, Biogen Idec, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis Soche, Serono, Teva); research support (Actelion, Novartis, Opexa). CL: Consulting fees (Acorda, Bayer, Biogen Idec, EMD Serono, Genzyme/Sanofi, Novartis, Pfizer, Questcor, Teva Neurosciences, UCB); speakers bureaus (Acorda, Bayer, Biogen Idec, EMD Serono, Genzyme/Sanofi, Novartis, Pfizer, Questcor, Teva Neurosciences, UCB); fees from non-CME services (Acorda, Bayer, Biogen Idec, EMD Serono, Genzyme/Sanofi, Novartis, Pfizer, Questcor, Teva Neurosciences, UCB); contracted research (Biogen Idec, Genzyme/Sanofi, Novartis, Teva Neurosciences, Vaccinex). **BK**: Consulting fees (Bayer Biogen Idec, Genzyme, Novartis, Plizer, Questcor, Serono, Terumo, Teva): speakers bureaus (Bayer, Biogen Idec, Genzyme, Novartis, Plizer, Questcor, Serono, Terumo, Teva): RG: Consulting fees (Biogen, BayerSchering, Elan Genzyme, Roche, Teva): ant/research support (Biogen, BaverSchering, Genzyme, Teva), **SC:** Employee of Genzyme, with ownership interest SB: Employee of Lincoln, mandated by Sanofi. FB: Employee of Genzyme. KRE: Consulting services (Biogen, Genzyme) speakers bureaus (Biogen, Genzyme, Novartis); research support (Biogen, Eli Lilly, Easai, Forum Pharmaceuticals, Genentech, Genzyme, Hoffman-La Roche, Novartis, Pfizer, Merz Pharmaceuticals Vaccinex)

#### Disclaimer

Teriflunomide is approved in many countries, including the US and the European Union, for the treat of relapsing multiple sclerosis or relapsing-remitting multiple sclerosis. This material may contair information that is outside of the approved labeling in some countries.

